Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced Solid Tumors
NCT02549937Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2015
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of surufatinib in solid tumor, biliary tract cancer (BTC), Pancreatic neuroendocrine tumor (PanNET), Neuroendocrine Neoplasm (NEN), soft tissue sarcoma (STS), sponsored by HUTCHMED. Started Nov 2015; status: completed.
02
Drugs
surufatinib
03
Conditions
solid tumorbiliary tract cancer (BTC)Pancreatic neuroendocrine tumor (PanNET)Neuroendocrine Neoplasm (NEN)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02549937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549937.